Targets

PD-1 / PD-L1

17 articles

Medicinal ChemistryJournal of Medicinal Chemistry

Tricyclic pteridinone yields an oral HPK1 inhibitor that pairs with anti-PD-1

  • Structure-guided scaffold hopping and ring optimization from a known diaminopyrimidine carboxamide HPK1 chemotype gave a new tricyclic pyrido[2,1-h]pteridin-6-one core.
  • Lead 29 is highly potent with strong kinase selectivity, blocks SLP-76 phosphorylation and boosts T-cell activation in Jurkat cells and human PBMCs.
  • It shows good oral exposure and, combined with anti-PD-1 in the CT26.WT syngeneic model, clearly improves tumor control.
PointsBased on the abstract

Tricyclisation plausibly pre-organises the hinge-binding conformation and cuts the entropic cost, so the design logic is easy to follow. The harder test is selectivity within the MAP4K family, notably GLK, and against T-cell kinases such as LCK, where off-target activity could undercut the immune benefit. The combination result also lacks a monotherapy arm and an inactive analogue to show it is on-target.

Medicinal ChemistryJournal of Medicinal Chemistry (ACS)

Coumarin-caged PD-L1 inhibitors stay silent in the dark and switch on with visible light

  • Two small-molecule PD-L1 inhibitors were masked with photolabile coumarin groups, at attachment points chosen from cocrystal binding modes.
  • In the dark the caged prodrugs were inactive; visible light released the parent inhibitors and restored T-cell function in PD-L1-dependent co-cultures.
  • The aim is local, on-demand checkpoint blockade that limits systemic immune toxicity, suited to superficial or light-accessible lesions.
PointsBased on the abstract

Dimerizing biaryl PD-L1 binders are already greasy and borderline for cell potency, so a bulky coumarin cage only helps if it truly kills binding in the dark. I'd want a residual-activity control on the uncleaved prodrug and on the photolysis byproduct. Also, visible light barely penetrates tissue, so red-shifted cages would be my next ask.

Medicinal ChemistryEuropean Journal of Medicinal Chemistry

Symmetric naphthoflavone degraders clear CYP1B1 and boost anti-PD-L1 response in colon tumor models

  • Two copies of an α-naphthoflavone CYP1B1 ligand flank a PEG linker, so whichever end is not bound in the active site can act as a hydrophobic degradation tag.
  • The lead degrades CYP1B1 selectively over CYP1A1 with no hook effect, through misfolding, HSP70/HSP90 recruitment and proteasomal clearance.
  • At a low dose it synergized with anti-PD-L1 in colon tumor models; a CDK4/6 degrader using the same tag hints at wider use.
PointsBased on the abstract

The symmetric design is neat, but the second ligand roughly doubles molecular weight and lipophilicity, so I'd worry about solubility, permeability and in vivo exposure before efficacy. Hydrophobic tags usually give only partial depletion compared with VHL/CRBN PROTACs. The missing controls are a CYP1B1 PROTAC at matched dose and the parent inhibitor, to separate degradation from enzymatic inhibition.

PharmacologyScience Translational Medicine

Regorafenib, nivolumab and chemotherapy reshape the gastric tumor microenvironment, exposing resistance targets

  • A phase 1b/2 trial tested first-line regorafenib, the PD-1 antibody nivolumab and chemotherapy in mismatch repair–proficient advanced gastric cancer; the primary end point was met, with a high objective response rate.
  • Single-cell RNA and T cell receptor sequencing of serial biopsies showed more tumor-reactive CD8 T cells and proinflammatory macrophages, and fewer suppressive regulatory T cells, CAFs, pericytes and tip cells.
  • At progression, regulatory T cells reexpanded and lipid-associated macrophage subsets emerged. In mouse resistance models, anti-CCR8 or anti-TREM2 antibodies with PD-1 blockade restored antitumor immunity.
PointsBased on the abstract

Which arm is doing the work? Regorafenib's VEGFR and CSF1R inhibition plausibly explains the drop in pericytes, tip cells and suppressive myeloid cells, but a single-arm combination can't separate that from chemo or PD-1 effects. The CCR8 and TREM2 mouse data are hypothesis-grade: syngeneic models rarely recapitulate acquired resistance, and anti-CCR8 depleting Tregs raises tumor-selectivity and on-target safety questions in humans.

Medicinal ChemistryACS Medicinal Chemistry Letters

N-acyl pyrimidine-biphenyl small molecules bind PD-L1, restore T cell activity and curb tumor growth in a syngeneic breast cancer model

  • A series of N-acyl pyrimidine-biphenyl analogues was designed as small-molecule PD-L1 inhibitors; A6 and A12 were potent binders in a reporter assay.
  • Molecular dynamics attributed A6's slight edge to persistent interaction with D122.
  • A6 disrupted PD-1/PD-L1 binding in ELISA, restored T cell activity, boosted cytokine secretion and enhanced T cell-mediated tumor cell killing.
  • In the syngeneic 4T1 model it suppressed tumor growth without systemic toxicity.
PointsBased on the abstract

Biphenyl cores are the familiar BMS-type PD-L1 pharmacophore, so novelty rides on the N-acyl pyrimidine. Those biphenyls induce PD-L1 dimerization, and the D122 story comes only from MD. I'd want a co-crystal or NMR, human versus mouse PD-L1 affinity (4T1 is murine), and a SPR KD with solubility data before trusting the potency ranking.

Medicinal ChemistryJournal of Medicinal Chemistry

Dual HDAC and PD-1/PD-L1 inhibitors tackle resistant melanoma

  • Six hybrids combine histone deacetylase inhibition with PD-1/PD-L1 blockade in one molecule.
  • Two leads differ in isoform preference, HDAC6-selective versus HDAC1-3; both disrupt the checkpoint pair and lower tumor cell viability in vitro.
  • The HDAC6 lead eased T cell exhaustion, boosted neutrophil and NK activity in vivo, and worked in BRAF-mutant melanoma, including vemurafenib-resistant cells.
  • The HDAC1-3 lead was cytotoxic but raised PD-L1 expression, so isoform choice matters.
PointsBased on the abstract

Set against dosing an HDAC inhibitor alongside a checkpoint antibody, one hybrid sidesteps PK mismatch but pays in size and lipophilicity, with a hydroxamate warhead on a biphenyl-type PD-L1 binder. PD-1/PD-L1 disruption needs confirming by HTRF and a cellular assay. The PD-L1 rise from the HDAC1-3 lead is a useful warning; HDAC6 looks the series to push.

Medicinal ChemistryACS Medicinal Chemistry Letters

Pyrimidine-biphenyl small molecules block PD-L1 and curb breast tumors in mice

  • N-acyl pyrimidine-biphenyl compounds were made as non-antibody PD-L1 blockers, since no small-molecule drug against this checkpoint is approved.
  • Reporter-cell screening flagged two hits; dynamics modeling tied the better one, A6, to stable contact with D122.
  • A6 weakened PD-1/PD-L1 binding in ELISA, far less potently than in cells.
  • In cells it revived T cell activity and tumor killing; in syngeneic 4T1 mice it slowed tumor growth without visible systemic toxicity.
PointsBased on the abstract

Cell potency outrunning ELISA potency is the pattern to watch. BMS-type biphenyl PD-L1 binders act by inducing PD-L1 dimerization, and cell readouts can hide cytotoxicity, so SPR/HTRF binding, a dimerization assay and an inactive analog should come before any D122 contact optimization. The next gate is whether 4T1 efficacy holds in human PD-L1 models.

Medicinal ChemistryJournal of Medicinal Chemistry

Cyclopropyl-linked dipeptide tail improves oral PD-L1 small molecules

  • A stereodefined cyclopropyl linker attaches polar groups to the solvent-exposed side of a biphenyl PD-L1 binder, allowing amino alcohols, amino acids, dipeptides and peptidomimetics to be compared.
  • SAR pointed to a dipeptide-bearing (1S,2S) isomer as a strong blocker of the PD-1/PD-L1 interaction with clear PD-L1 binding.
  • It showed better solubility, microsomal stability and oral exposure in mice, and orally dosed it slowed melanoma growth with immune activation and good tolerability.
PointsBased on the abstract

Putting the polar tail on a rigid cyclopropyl instead of a floppy chain is a smart way to pay the entropy bill, and the stereo-dependence of (1S,2S) hints the vector really matters. But biphenyl PD-L1 binders are known for inducing dimerization, so I'd want a crystal structure or at least a clear dimer assay, plus a human PD-L1 comparison, before trusting the mouse efficacy.

PharmacologyBiochemical Pharmacology

Dauricine lowers T-cell PD-1 through lysosomal degradation and curbs melanoma growth

  • The natural alkaloid dauricine reduced PD-1 levels in Jurkat T cells via the endosomal–lysosomal route, accompanied by increased ubiquitination.
  • Lower PD-1 coincided with stronger T-cell killing of melanoma cells; dauricine also directly caused apoptosis and G1 arrest in the tumor cells.
  • In melanoma xenograft mice it increased T-cell infiltration and slowed tumor growth.
PointsBased on the abstract

Dauricine hits tumor cells directly, so the xenograft benefit can't be credited to PD-1 loss. Worse, a standard xenograft needs immunodeficient hosts, which undercuts a T-cell mechanism; a syngeneic model with PD-1 reconstitution or a degradation-resistant PD-1 mutant would settle it. Target-binding evidence is also absent: what engages PD-1 or its trafficking machinery is still unknown.

Computational & AIbioRxiv

Fixed-stage LLM agent with literature access designs protein binders from a single natural-language prompt

  • LPT chains fixed LLM stages, each running a bounded tool-using loop, so binder design starts from one plain-language request while keeping token use and compute low.
  • The stages can query a curated database of about 14,000 digested papers; a model with access answered most held-out questions drawn from it, whereas one without access answered none.
  • Three end-to-end campaigns targeted CALCRL/RAMP1, PD-1/PD-L1 and PVR-TIGIT. Support is in silico only, from agreement across several folding models, with no experimental testing reported.
PointsBased on the abstract

The novelty in LPT is a bounded orchestration layer, not a new binder-design method, and its literature test only shows retrieval beats no retrieval, a low bar. Folding-model agreement is weak evidence without wet-lab data, since those models share training biases. On my project, hit rates against plain RFdiffusion pipelines would settle it.

PharmacologyScience Translational Medicine

CCR8xCD3 T cell engager clears tumor-infiltrating Tregs and slows growth in mouse tumor models

  • A bispecific antibody links CD3 on T cells to CCR8, which is enriched on tumor-infiltrating Tregs, so T cells rather than NK cells carry out the depletion.
  • It selectively removed Tregs in human solid tumor samples in vitro.
  • In several syngeneic mouse models with differing T cell infiltration, it slowed tumor growth, alone or alongside anti-PD-L1.
PointsBased on the abstract

Swapping NK-mediated ADCC for T cell redirection is the bet here, and it's a double-edged one: CD3 engagers bring cytokine release and on-target hits on any CCR8+ activated T cell. Syngeneic wins say little about human Treg biology, since mouse CCR8 expression differs. Without the primate PK and tolerability data, I wouldn't move forward.

Medicinal ChemistryJournal of Medicinal Chemistry (ACS)

Scaffold Hopping Yields a Tricyclic, Orally Available HPK1 Inhibitor That Boosts Anti-PD-1 in Mice

  • Starting from a known diaminopyrimidine carboxamide HPK1 inhibitor, structure-guided scaffold hopping and ring-system tuning produced a new tricyclic pyrido[2,1-h]pteridin-6-one core.
  • The lead compound, 29, was strongly potent against HPK1 and highly selective across other kinases.
  • In cells, it blocked HPK1-driven SLP-76 phosphorylation and strengthened T-cell activation in Jurkat cells and human PBMCs.
  • It was well absorbed orally and, combined with anti-PD-1, clearly improved tumor control in a CT26.WT syngeneic mouse model.
PointsBased on the abstract

Locking the hinge-binding pharmacophore into a tricycle is a sensible way out of the crowded diaminopyrimidine carboxamide space. Rigidifying the core should pay the conformational penalty up front and help kinome selectivity, which matters because MAP4K relatives are the usual liability. Exposure data and the ring-fused synthetic route would decide how excited I get.

PharmacologybioRxiv

Small molecule that stabilizes CHI3L1–Gal3BP shifts glioblastoma macrophages and adds to anti-PD-1

  • A screen found LZ6, which strengthens CHI3L1 binding to Gal3BP and reduces galectin-3 engagement in vitro.
  • It pushed macrophages toward an anti-tumor state in patient-derived glioblastoma cultures and orthotopic GL261 tumors.
  • Oral dosing extended survival in mice, and more so alongside anti-PD-1.
PointsBased on the abstract

Stabilizing a protein complex rather than blocking it is an unusual pharmacological idea, and the oral survival benefit in an orthotopic model is the interesting part. But GL261 is a notoriously immunogenic mouse line that flatters checkpoint combinations, and glioblastoma has repeatedly failed to follow it. I'd need brain exposure and target engagement data before taking the mechanism seriously.

Medicinal ChemistryJournal of Medicinal Chemistry

A dual A2A/A2B antagonist chemotype that sensitizes MSS colorectal tumors to anti-PD-1

  • Imidazo[1,2-a]pyrazine-ureas emerged as a new chemotype of dual A2A/A2B adenosine receptor antagonists.
  • SAR showed that iodination at the 3-position of the core improved affinity and functional antagonism; simulations suggest distinct binding modes in the two orthosteric pockets.
  • The lead restored T-cell cytokine production, increased T-cell infiltration, and boosted anti-PD-1 efficacy in CD73-high colorectal models.
PointsBased on the abstract

Dual A2A/A2B blockade makes sense in CD73-high tumors, where adenosine hits both receptors, but A2B selectivity versus A1 and A3 is usually the hard part. A 3-iodo group is a flag for me: it helps affinity but invites questions about metabolic stability and lipophilic efficiency. Whether the iodine can be swapped for a smaller or less lipophilic group is the next experiment.

Industry NewsAstraZeneca / Summit TherapeuticsFierce Biotech

AstraZeneca Takes a $2B Stake in Summit to Pair Ivonescimab with Its ADCs

  • AstraZeneca is buying $2B of convertible preferred stock, giving it about 12% of Summit's common stock (about 10.6% fully diluted).
  • The first combination pairs Summit's PD-1xVEGF bispecific ivonescimab with AstraZeneca's CLDN18.2-directed ADC in gastrointestinal cancers; a memorandum of understanding covers a broader program with more AstraZeneca ADCs.
PointsBased on public reports

This is AstraZeneca buying a seat rather than a pipeline: equity plus combination rights instead of an acquisition or license, keeping it close to a PD-1xVEGF class it doesn't own without paying for the asset outright. The bet is that ADC plus PD-1xVEGF combinations become a next oncology backbone, with AstraZeneca's ADC portfolio as the partner of choice. The broader MOU is non-binding, so definitive terms are the thing to watch.

Medicinal ChemistryJournal of Medicinal Chemistry (ACS)

Hsc70-Recruiting Degraders Exploit Chaperone-Mediated Autophagy for Targeted Protein Degradation

  • Researchers developed Hsc70-Mediated Targeting Chimeras (Hsc70TACs), bifunctional small molecules that link an Hsc70-binding ligand to a ligand for a protein of interest, directing target degradation through chaperone-mediated autophagy rather than the ubiquitin-proteasome pathway used by PROTACs.
  • The approach is proposed to extend the range of degradable targets, including certain cytosolic and cell-membrane proteins, and to offer an alternative route that may help address resistance risks associated with proteasome-dependent degraders.
  • Degradation activity was demonstrated across multiple protein classes, including the transcriptional regulator BRD4, the regulatory protein MDM2, and the cell-membrane immune checkpoint protein PD-L1, across diverse cellular contexts.
  • A lead BRD4-directed compound, B-2, showed favorable pharmacokinetic behavior and produced robust BRD4 degradation in vivo, supporting continued development of the Hsc70TAC modality.
PointsBased on the abstract

A degradation route that bypasses CRBN/VHL entirely is worth my attention regardless of target — CMA recruitment sidesteps the ubiquitin-proteasome toolbox, so it should be orthogonal to the resistance mechanisms (neosubstrate mutation, E3 downregulation) that kill PROTAC leads in the clinic. PD-L1 is the result I'd chase: pulling a membrane protein through chaperone-mediated autophagy via LAMP2A translocation is something UPS-based PROTACs structurally can't do. My skepticism sits with the Hsc70 arm — KFERQ-motif engagement is promiscuous by design, so selectivity and off-target chaperone-client disruption need real scrutiny before I trust the SAR. B-2's in vivo PK and clean BRD4 knockdown at least de-risks synthesis/linker chemistry enough to treat this as a platform, not just a proof of concept.

Industry NewsAkeso / Summit TherapeuticsEndpoints News

Ivonescimab Beats Keytruda on Survival in Phase 3 NSCLC Trial

  • Ivonescimab (Akeso/Summit's PD-1 x VEGF bispecific) reduced risk of death by 27% vs. Merck's Keytruda in the Phase 3 HARMONi-2 trial.
  • Trial enrolled treatment-naive, PD-L1-positive advanced NSCLC patients in China.
  • Median overall survival: 30.75 months for ivonescimab vs. 22.57 months for Keytruda.
  • Adds to the trial's earlier primary PFS win — a 49% reduction in progression/death risk (11.14 vs. 5.82 months).
  • Fourth Phase 3 ivonescimab readout to hit its OS endpoint, bolstering the case for combining PD-1 blockade with anti-VEGF activity in one bispecific.
  • Akeso (China) and Summit Therapeutics (ex-China licensee) are co-developing the drug as a head-to-head Keytruda challenger.
PointsBased on public reports

A head-to-head overall-survival win over Keytruda is about as rare an event as oncology drug development produces — Merck's franchise has fended off nearly every direct challenger for a decade, and ivonescimab is now four-for-four on OS across its Phase 3 program. That changes the calculus for Summit, whose ex-China license from Akeso looked speculative at signing and now looks like one of the shrewder biotech deals in recent memory — every data cut adds leverage for future pricing, partnering, or M&A conversations. It's also the clearest advertisement yet for the China-originated-asset licensing wave Western biotechs have been chasing: a domestically-developed bispecific outrunning the world's best-selling drug in its own trial. For Merck, it lands squarely as Keytruda nears patent cliff — this isn't a niche subtype win, it's a direct share threat in frontline NSCLC, the franchise's core indication.